RESEARCH MONOGRAPH · KDC-MN-151

Lemborexant

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

70/100

The cleaner dual orexin antagonist with the better half-life profile, still a modest effect size

Lemborexant (Dayvigo) is Eisai's dual orexin receptor antagonist, approved in 2019 as the second DORA on market. The differentiation versus suvorexant is mostly in the pharmacokinetic profile: half-life of around 17 to 19 hours but a faster early absorption profile, which paradoxically means less morning residual effects than suvorexant despite the longer apparent half-life. This is because the effective receptor occupancy at OX2R during the daytime window after dosing falls below the threshold for next-day sedation more cleanly than with suvorexant.

The SUNRISE trial program showed efficacy in insomnia with effect sizes similar to suvorexant. SUNRISE-2 was a head-to-head against placebo and against zolpidem, with lemborexant showing comparable or modestly better efficacy than zolpidem on sleep maintenance endpoints without the next-morning psychomotor impairment that zolpidem produces.

What we like: the receptor pharmacology is in the same place as suvorexant (dual OX1R/OX2R antagonism, comparable affinities) but the PK profile is meaningfully better. From a clinical and research perspective lemborexant is probably the cleaner choice in the DORA class as it currently stands. Daridorexant is the newer entry which may push the class further along.

What we dont like: the absolute effect sizes are still modest compared to the marketing hype around DORAs as a major advance over hypnotics. The DORAs are meaningfully different mechanism-wise from BZRAs but they're not important for insomnia treatment overall. Most people who dont respond to behavioral interventions and have tried a BZRA may get modest additional benefit from a DORA; that's not nothing but its not a major leap.

Mechanism: well-mapped at the OX1R/OX2R level. The faster offset of clinical sedation despite the long apparent half-life relates to the receptor-occupancy/concentration relationship being non-linear, which is interesting pharmacology.

Sourcing: novel small molecule, branded pharmaceutical, research-grade is available from major chemical suppliers though with less widespread distribution than suvorexant given how new it is. Quality from reputable suppliers is fine.

The cleaner DORA. Underrated relative to suvorexant which has more brand recognition. If you're studying orexin pharmacology this is probably the tool to reach for.

Evidence: 75
Mechanism: 85
Reliability: 72
Safety: 80
Sourcing: 65
Value: 50
Signal: 60
Staying power: 70

Plain-language summary Intrigue 72 / 100

Lemborexant, sold as Dayvigo, is a second-generation dual orexin receptor antagonist with improved selectivity for OX2 over OX1. FDA-approved for insomnia in 2019. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Dual orexin receptor antagonist

A second DORA FDA-approved as Dayvigo (2019) for insomnia, with shorter half-life and reduced next-day residual effects than suvorexant.

Abstract

Lemborexant (Dayvigo; E2006; CAS 1369764-02-2) is a dual orexin receptor antagonist developed by Eisai and approved by the FDA in 2019 for insomnia. The compound has shorter plasma half-life (17 to 19 hours, but the active fraction declines more rapidly than with suvorexant) and reduced next-day residual sedation in clinical trials. Mechanism is the same as suvorexant: competitive OX1R and OX2R antagonism. Reported research dose ranges in the literature are described in the source publications. Schedule IV.

Mechanism of action

Dual orexin receptor (OX1R, OX2R) antagonist; shorter functional duration than suvorexant.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Rosenberg R, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia. JAMA Netw Open 2019.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-151

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Lemborexant

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs